Recent News

SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma

AUA 2021: KEYNOTE-564 Focuses on Adjuvant Immunotherapy for Renal Cell Carcinoma

SOHO 2021: Early Results With Magrolimab Plus Azacitidine in AML

SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma

Chemotherapy and Immunotherapy for KEAP1/NFE2L2-Mutant Lung Cancer

Immune Checkpoint Inhibition in Metastatic Kidney Cancer: Racial Differences in Outcomes?

Amivantamb Under Study in Treatment of EGFR Exon 20 Insertion–Mutated NSCLC

Pembrolizumab Receives Full FDA Approval for Certain Patients With Advanced Urothelial Carcinoma

Manufacturer Withdraws Atezolizumab’s U.S. Indication in Triple-Negative Breast Cancer

Reversible Aminotransferase Elevation in Patients Treated With Pembrolizumab/Axitinib for Kidney Cancer

Does Antibiotic Therapy Impact Outcomes to Chemoimmunotherapy in NSCLC?

Combination Checkpoint Antibody Treatment in Cutaneous Squamous Cell Carcinoma

FDA Approves Nivolumab as First Adjuvant Treatment for High-Risk Urothelial Carcinoma

Initial Results From Cohort A of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Myeloma

Incidence of Neutropenia With Venetoclax and Obinutuzumab in CLL

Urothelial Carcinoma: Prognostic Factors Associated With Immune Checkpoint Inhibitors

Lenvatinib Plus Pembrolizumab Approved by FDA for Advanced Renal Cell Carcinoma

Atezolizumab Receives Priority Review From the FDA in Early NSCLC

ICARIA-MM: Updated Results With Isatuximab-Based Therapy for Resistant Myeloma

Novel Monoclonal Antibody and Chemotherapy Combination Under Study in Resistant AML

Atezolizumab in Resistant Advanced Urothelial Cancer: Prognostic Significance of Pretreatment Factors

JAVELIN Renal 101 Trial: Second-Line Treatment With Axitinib Plus Avelumab in Kidney Cancer

PET/CT Images: Measuring PD-L1 Status and Predicting Response to Immunotherapy in NSCLC

Use of Avelumab for Oligoprogression in Advanced Merkel Cell Carcinoma: Case Report

Adding Atezolizumab to Chemotherapy for Muscle-Invasive Bladder Cancer

Checking Checkpoint Inhibitor Effectiveness in Immunocompromised Patients With Advanced Skin Cancer

MET-Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study

Patterns of PD-L1 Expression in NSCLC Harboring Driver Oncogene Mutations Including NTRK Fusions

Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC

Update From EV-103: Enfortumab Vedotin-ejfv Plus Pembrolizumab for Advanced Urothelial Carcinoma

Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer

Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?

Subcutaneous Use of BCMA-CD3 Bispecific Monoclonal Antibody in Myeloma

Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?

Adding Daratumumab to Combination Therapy for Newly Diagnosed Multiple Myeloma

Choice of Platinum in First Line Treatment of Advanced Urothelial Carcinoma in the Era of Second-Line Immunotherapy

Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results